Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Corvus Pharmaceuticals ( (CRVS) ) has provided an update.
On January 21, 2026, Corvus Pharmaceuticals entered into an underwriting agreement with Jefferies and Goldman Sachs for an underwritten public offering of 7,900,677 shares of common stock at $22.15 per share, with the underwriters purchasing at $20.821 per share and holding a 30-day option to buy an additional 1,185,101 shares. The option was fully exercised on January 22, 2026, and the offering, expected to close on January 23, 2026, is anticipated to generate approximately $188.3 million in net proceeds, which Corvus plans to use for working capital and general corporate purposes, including capital spending, research and development for its late-stage clinical trials, and sales, marketing and administrative expenses, bolstering its funding base for ongoing and future development programs.
The most recent analyst rating on (CRVS) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.
Spark’s Take on CRVS Stock
According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.
The score is driven most by strong technical trend signals and positive clinical/catalyst momentum (earnings call and the latest Phase 1 update). These positives are tempered by weak financial performance typical of a pre-revenue biotech—ongoing losses and cash burn—and limited valuation support given the negative P/E and no dividend yield data.
To see Spark’s full report on CRVS stock, click here.
More about Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for immune-related diseases and cancers, with a pipeline that includes a Phase 3 program in T cell lymphoma and Phase 2 trials in atopic dermatitis, hidradenitis suppurativa and asthma.
Average Trading Volume: 3,143,665
Technical Sentiment Signal: Buy
Current Market Cap: $1.6B
Find detailed analytics on CRVS stock on TipRanks’ Stock Analysis page.